Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 7/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005107 | 0.86 | ACLY (0.59) | ACLYMAOACYP11B2KMT2A | |
| SCHEMBL22005117 | 0.84 | ACLY (0.53) | ACLYFTOEIF4EMAOAMAOB | |
| SCHEMBL22003821 | 0.74 | ACLY (0.51) | ACLYGPR35KMT2A | |
| SCHEMBL22004231 | 0.72 | ACLY (1.00) | ACLY | |
| SCHEMBL22004125 | 0.72 | ACLY (0.49) | ACLYMAOACYP11B2KMT2A | |
| SCHEMBL22005109 | 0.71 | ACLY (0.56) | ACLYMAOAKMT2A | |
| SCHEMBL20916534 | 0.70 | MAOB (0.44) | ACLYMAOAMAOB | |
| SCHEMBL5789239 | 0.70 | ACLY (0.46) | ACLYKMT2A | |
| SCHEMBL22005143 | 0.67 | ACLY (0.48) | ACLYKMT2A | |
| SCHEMBL5790230 | 0.67 | ACLY (0.49) | ACLYKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885FTO 2983/4885EIF4E 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.